⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 12, 2024Frontiers in OncologyOpen Access

2-methoxyestradiol inhibits the malignant behavior of triple negative breast cancer cells by altering their miRNome

Ramadevi Subramani A. Chatterjee Diego A. Pedroza Seeta Poudel Preetha Rajkumar Jeffrey Annabi Elizabeth Penner Rajkumar Lakshmanaswamy

View Full Paper

Ask AI

Bookmark

Share

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with no effective targeted treatment currently available. Estrogen and its metabolites influence the growth of mammary cancer. Previously, we demonstrated the anti-cancer effects of 2-methoxyestradiol (2ME2) on mammary carcinogenesis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Subramani et al. (2024) studied this question.

synapsesocial.com/papers/68e58bb0b6db643587527c65 https://doi.org/10.3389/fonc.2024.1371792

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effect of 2‐methoxyestradiol on mammary tumor initiation and progression2024 · 2 citations
22-Methoxyestradiol, an Endogenous 17β-Estradiol Metabolite, Induces Antimitogenic and Apoptotic Actions in Oli-Neu – Oligodendroglial Precursor Cells and Triggers Endoreduplication via p53 Pathway2024
32-Methoxyestradiol, an Endogenous 17β-Estradiol Metabolite, Induces Antimitogenic and Apoptotic Actions in Oligodendroglial Precursor Cells and Triggers Endoreduplication via the p53 Pathway2024 · 2 citations
4Abstract 2054: Melatonin and estradiol action on let-7 family members in triple-negative breast cancer cells.Original Research · 2026
5Epithelial to Mesenchymal Transition as a Therapeutic Target forMicroRNAs in Triple Negative Breast CancerReview · 2026

More related papers

Metastasis of triple negative breast cancer is regulated by a targetable miR-342-E2F network2026
Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer2025
Epigenetic modulators in triple-negative breast cancer: epigenetic modifications and future treatment perspectives2026

More from Frontiers in Oncology

Case Report: A case of early rapid recurrence of a primary intracranial alveolar soft part sarcoma with high proliferative activity and complex molecular variationsThu,
Targeting the MLN64/STARD3-cholesterol axis disrupts tight junction remodelling and attenuates gastric cancer aggressivenessThu,